3 курс / Фармакология / Интеллектуальные_липидные_наноконтейнеры_в_адресной_доставке_лекарственных

239

655.Westerfeld N., Zurbriggen R. (2005) Peptides delivered by immunostimulating reconstituted influenza virosomes. J.Pept.Sci., 11, 707-712.

656.Zurbriggen R., Amacker M., Kammer A.R., Westerfeld N., Borghgraef P., Van Leuven F., Van d.A., I, Wera S. (2005) Virosome-based active immunization targets soluble amyloid species rather than plaques in a transgenic mouse model of Alzheimer's disease.

J.Mol.Neurosci., 27, 157-166.

657.Schumacher R., Amacker M., Neuhaus D., Rosenthal R., Groeper C., Heberer M., Spagnoli G.C., Zurbriggen R., Adamina M. (2005) Efficient induction of tumoricidal cytotoxic T lymphocytes by HLA-A0201 restricted, melanoma associated, L(27)Melan- A/MART-1(26-35) peptide encapsulated into virosomes in vitro. Vaccine, 23, 5572-5582.

658.Hunziker I.P., Zurbriggen R., Glueck R., Engler O.B., Reichen J., Dai W.J., Pichler W.J., Cerny A. (2001) Perspectives: towards a peptide-based vaccine against hepatitis C virus.

Mol.Immunol., 38, 475-484.

659.Kursteiner O., Moser C., Lazar H., Durrer P. (2006) Inflexal V – the influenza vaccine with the lowest ovalbumin content. Vaccine, 24, 6632-6635.

660.Schumacher R., Adamina M., Zurbriggen R., Bolli M., Padovan E., Zajac P., Heberer M., Spagnoli G.C. (2004) Influenza virosomes enhance class I restricted CTL induction through CD4+ T cell activation. Vaccine, 22, 714-723.

661.Zurbriggen R. (2003) Immunostimulating reconstituted influenza virosomes. Vaccine, 21, 921-924.

662.Pfeiffer B., Peduzzi E., Moehle K., Zurbriggen R., Gluck R., Pluschke G., Robinson J.A. (2003) A virosome-mimotope approach to synthetic vaccine design and optimization: synthesis, conformation, and immune recognition of a potential malaria-vaccine candidate.

Angew.Chem.Int.Ed Engl., 42, 2368-2371.

663.Amacker M., Engler O., Kammer A.R., Vadrucci S., Oberholzer D., Cerny A., Zurbriggen R. (2005) Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells. Int.Immunol., 17, 695-704.

664.Angel J., Chaperot L., Molens J.P., Mezin P., Amacker M., Zurbriggen R., Grichine A., Plumas J. (2007) Virosome-mediated delivery of tumor antigen to plasmacytoid dendritic cells. Vaccine, 25, 3913-3921.

665.Kammer A.R., Amacker M., Rasi S., Westerfeld N., Gremion C., Neuhaus D., Zurbriggen R. (2007) A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses. Vaccine, 25, 7065-7074.

666.Skehel J.J., Wiley D.C. (2000) Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu.Rev.Biochem., 69, 531-569.

667.Ito T., Couceiro J.N., Kelm S., Baum L.G., Krauss S., Castrucci M.R., Donatelli I., Kida H., Paulson J.C., Webster R.G., Kawaoka Y. (1998) Molecular basis for the generation in pigs of influenza A viruses with pandemic potential. J.Virol., 72, 7367-7373.

668.Lakadamyali M., Rust M.J., Zhuang X. (2004) Endocytosis of influenza viruses.

Microbes.Infect., 6, 929-936.

669.Smith A.E., Helenius A. (2004) How viruses enter animal cells. Science, 304, 237-242.

670.Bron R., Ortiz A., Dijkstra J., Stegmann T., Wilschut J. (1993) Preparation, properties, and applications of reconstituted influenza virus envelopes (virosomes). Methods Enzymol., 220, 313-331.

671.McElhaney J.E. (2005) The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine, 23, S10-S25.

672.Bungener L., Huckriede A., Wilschut J., Daemen T. (2002) Delivery of protein antigens to the immune system by fusion-active virosomes: a comparison with liposomes and ISCOMs. Biosci.Rep., 22, 323-338.

673.Bron R., Ortiz A., Wilschut J. (1994) Cellular cytoplasmic delivery of a polypeptide toxin by reconstituted influenza virus envelopes (virosomes). Biochemistry, 33, 9110-9117.

674.Huckriede A., Bungener L., ter Veer W., Holtrop M., Daemen T., Palache A.M., Wilschut J. (2003) Influenza virosomes: combining optimal presentation of hemagglutinin with immunopotentiating activity. Vaccine, 21, 925-931.

675.Felnerova D., Viret J.F., Gluck R., Moser C. (2004) Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr.Opin.Biotechnol., 15, 518-529.

240

676.Adamina M., Weber W.P., Rosenthal R., Schumacher R., Zajac P., Guller U., Frey D.M., Oertli D., Zuber M., Heberer M., Spagnoli G.C. (2008) Heterologous prime-boost immunotherapy of melanoma patients with Influenza virosomes, and recombinant Vaccinia virus encoding 5 melanoma epitopes and 3 co-stimulatory molecules. A multi-centre phase I/II open labeled clinical trial. Contemp.Clin.Trials, 29, 165-181.

677.Herzog C., Hartmann K., Kunzi V., Kursteiner O., Mischler R., Lazar H., Gluck R. (2009) Eleven years of Inflexal((R)) V-A virosomal adjuvanted influenza vaccine. Vaccine, 27, 4381-4387.

678.Kunzi V., Dornseiff M., Horwath J., Hartmann K. (2009) Safe vaccination of children with a virosomal adjuvanted influenza vaccine. Vaccine, 27, 1261-1265.

679.Esposito S., Gasparini C., Martelli A., Zenga A., Tremolati E., Varin E., Marseglia G.L., Fiocchi A., Principi N. (2008) Safe administration of an inactivated virosomal adjuvanted influenza vaccine in asthmatic children with egg allergy. Vaccine, 26, 4664-4668.

680.de Bruijn I.A., Nauta J., Gerez L., Palache A.M. (2006) The virosomal influenza vaccine Invivac: immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad in elderly subjects. Vaccine, 24, 6629-6631.

681.de B., I, Meyer I., Gerez L., Nauta J., Giezeman K., Palache B. (2007) Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. Vaccine, 26, 119-127.

682.Bovier P.A. (2008) Epaxal: a virosomal vaccine to prevent hepatitis A infection.

Expert.Rev.Vaccines., 7, 1141-1150.

683.Bovier P.A., Farinelli T., Loutan L. (2005) Interchangeability and tolerability of a virosomal and an aluminum-adsorbed hepatitis A vaccine. Vaccine, 23, 2424-2429.

684.D'Acremont V., Herzog C., Genton B. (2006) Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly. J.Travel.Med., 13, 78-83.

685.Van Der Wielen M., Vertruyen A., Froesner G., Ibanez R., Hunt M., Herzog C., Van Damme P. (2007) Immunogenicity and safety of a pediatric dose of a virosome-adjuvanted hepatitis A vaccine: a controlled trial in children aged 1-16 years. Pediatr.Infect.Dis.J., 26, 705-710.

686.Dagan R., Amir J., Livni G., Greenberg D., Abu-Abed J., Guy L., Ashkenazi S., Foresner G., Tewald F., Schatzl H.M., Hoffmann D., Ibanez R., Herzog C. (2007) Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial. Pediatr.Infect.Dis.J., 26, 787-793.

687.Usonis V., Bakasenas V., Valentelis R., Katiliene G., Vidzeniene D., Herzog C. (2003) Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal). Vaccine, 21, 4588-4592.

688.Tyagi R.K., Sharma P.K., Vyas S.P., Mehta A. (2008) Various carrier system(s)- mediated genetic vaccination strategies against malaria. Expert.Rev.Vaccines., 7, 499-520.

689.Malkin E., Dubovsky F., Moree M. (2006) Progress towards the development of malaria vaccines. Trends Parasitol., 22, 292-295.

690.Okitsu S.L., Silvie O., Westerfeld N., Curcic M., Kammer A.R., Mueller M.S., Sauerwein R.W., Robinson J.A., Genton B., Mazier D., Zurbriggen R., Pluschke G. (2007) A virosomal malaria peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial. PLoS.ONE., 2, e1278.

691.Thompson F.M., Porter D.W., Okitsu S.L., Westerfeld N., Vogel D., Todryk S., Poulton I., Correa S., Hutchings C., Berthoud T., Dunachie S., Andrews L., Williams J.L., Sinden R., Gilbert S.C., Pluschke G., Zurbriggen R., Hill A.V. (2008) Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. PLoS.ONE., 3, e1493.

692.Peduzzi E., Westerfeld N., Zurbriggen R., Pluschke G., Daubenberger C.A. (2008) Contribution of influenza immunity and virosomal-formulated synthetic peptide to cellular immune responses in a phase I subunit malaria vaccine trial. Clin.Immunol., 127, 188-197.

693.Cavanagh D.R., Remarque E.J., Sauerwein R.W., Hermsen C.C., Luty A.J. (2008) Influenza virosomes: a flu jab for malaria? Trends Parasitol., 24, 382-385.

241

694.Spohn R., Buwitt-Beckmann U., Brock R., Jung G., Ulmer A.J., Wiesmuller K.H. (2004) Synthetic lipopeptide adjuvants and Toll-like receptor 2 – structure-activity relationships. Vaccine, 22, 2494-2499.

695.de Vries J.J., Bungener L., ter Veer W., van Alphen L., van der L.P., Wilschut J., Huckriede A. (2009) Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity. Vaccine, 27, 947-955.

696.de Jonge J., Leenhouts J.M., Holtrop M., Schoen P., Scherrer P., Cullis P.R., Wilschut J., Huckriede A. (2007) Cellular gene transfer mediated by influenza virosomes with encapsulated plasmid DNA. Biochem.J., 405, 41-49.

697.Waelti E.R., Gluck R. (1998) Delivery to cancer cells of antisense L-myc oligonucleotides incorporated in fusogenic, cationic-lipid-reconstituted influenza-virus envelopes (cationic virosomes). Int.J.Cancer, 77, 728-733.

698.Huckriede A., de Jonge J., Holtrop M., Wilschut J. (2007) Cellular delivery of siRNA mediated by fusion-active virosomes. J.Liposome Res., 17, 39-47.

699.de Jonge J., Schoen P., ter Veer W., Stegmann T., Wilschut J., Huckriede A. (2006) Use of a dialyzable short-chain phospholipid for efficient solubilization and reconstitution of influenza virus envelopes. Biochim.Biophys.Acta, 1758, 527-536.

700.Subramanian N., Mani P., Roy S., Gnanasundram S.V., Sarkar D.P., Das S. (2009) Targeted delivery of hepatitis C virus specific shRNA in mouse liver using Sendai virosomes. J.Gen.Virol., 90, 1812-1819.

701.Bramwell V.W., Perrie Y. (2005) Particulate delivery systems for vaccines. Crit Rev.Ther.Drug Carrier Syst., 22, 151-214.

702.Abdulhaqq S.A., Weiner D.B. (2008) DNA vaccines: developing new strategies to enhance immune responses. Immunol.Res., 42, 219-232.

703.Lu S., Wang S., Grimes-Serrano J.M. (2008) Current progress of DNA vaccine studies in humans. Expert.Rev.Vaccines., 7, 175-191.

704.Rice J., Ottensmeier C.H., Stevenson F.K. (2008) DNA vaccines: precision tools for activating effective immunity against cancer. Nat.Rev.Cancer, 8, 108-120.

705.Uchida M., Li X.W., Mertens P., Alpar H.O. (2009) Transfection by particle bombardment: Delivery of plasmid DNA into mammalian cells using gene gun. Biochim.Biophys.Acta.

706.Leitner W.W., Baker M.C., Berenberg T.L., Lu M.C., Yannie P.J., Udey M.C. (2009) Enhancement of DNA tumor vaccine efficacy by gene gun-mediated codelivery of threshold amounts of plasmid-encoded helper antigen. Blood, 113, 37-45.

707.Goudy K.S., Wang B., Tisch R. (2008) Gene gun-mediated DNA vaccination enhances antigen-specific immunotherapy at a late preclinical stage of type 1 diabetes in nonobese diabetic mice. Clin.Immunol., 129, 49-57.

708.Wang S., Zhang C., Zhang L., Li J., Huang Z., Lu S. (2008) The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods. Vaccine, 26, 2100-2110.

709.Hermida R.C., Fernandez J.R., Ayala D.E., Mojon A., Alonso I., Smolensky M. (2001) Circadian rhythm of double (rate-pressure) product in healthy normotensive young subjects.

Chronobiol.Int., 18, 475-489.

710.Gref R., Minamitake Y., Peracchia M.T., Trubetskoy V., Torchilin V., Langer R. (1994) Biodegradable long-circulating polymeric nanospheres. Science, 263, 1600-1603.

711.Frank M.M., Fries L.F. (1991) The role of complement in inflammation and phagocytosis. Immunol.Today, 12, 322-326.

712.Gaucher G., Asahina K., Wang J., Leroux J.C. (2009) Effect of poly(N-vinyl- pyrrolidone)-block-poly(D,L-lactide) as coating agent on the opsonization, phagocytosis, and pharmacokinetics of biodegradable nanoparticles. Biomacromolecules., 10, 408-416.

713.Owens D.E., III, Peppas N.A. (2006) Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int.J.Pharm., 307, 93-102.

714.Moghimi S.M., Szebeni J. (2003) Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog.Lipid Res., 42, 463-478.

242

715.Ameller T., Marsaud V., Legrand P., Gref R., Barratt G., Renoir J.M. (2003) Polyester-poly(ethylene glycol) nanoparticles loaded with the pure antiestrogen RU 58668: physicochemical and opsonization properties. Pharm.Res., 20, 1063-1070.

716.Choi H.S., Liu W., Misra P., Tanaka E., Zimmer J.P., Itty I.B., Bawendi M.G., Frangioni J.V. (2007) Renal clearance of quantum dots. Nat.Biotechnol., 25, 1165-1170.

717.Peracchia M.T., Fattal E., Desmaile D., Besnard M., Noel J.P., Gomis J.M., Appel M., d'Angelo J., Couvreur P. (1999) Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J.Control Release, 60, 121-128.

718.Maurer-Jones M.A., Bantz K.C., Love S.A., Marquis B.J., Haynes C.L. (2009) Toxicity of therapeutic nanoparticles. Nanomed., 4, 219-241.

719.Huang G., Zhang N., Bi X., Dou M. (2008) Solid lipid nanoparticles of temozolomide: potential reduction of cardial and nephric toxicity. Int.J.Pharm., 355, 314-320.

720.Choi S.J., Oh J.M., Park T., Choy J.H. (2007) Cellular toxicity of inorganic hydroxide nanoparticles. J.Nanosci.Nanotechnol., 7, 4017-4020.

721.Gajdosikova A., Gajdosik A., Koneracka M., Zavisova V., Stvrtina S., Krchnarova V., Kopcansky P., Tomasovicova N., Stolc S., Timko M. (2006) Acute toxicity of magnetic nanoparticles in mice. Neuro.Endocrinol.Lett., 27, 96-99.

722.Weyhers H., Ehlers S., Hahn H., Souto E.B., Muller R.H. (2006) Solid lipid nanoparticles (SLN) – effects of lipid composition on in vitro degradation and in vivo toxicity. Pharmazie, 61, 539-544.

723.Fiorito S., Serafino A., Andreola F., Togna A., Togna G. (2006) Toxicity and biocompatibility of carbon nanoparticles. J.Nanosci.Nanotechnol., 6, 591-599.

724.Kaul G., Amiji M. (2002) Long-circulating poly(ethylene glycol)-modified gelatin nanoparticles for intracellular delivery. Pharm.Res., 19, 1061-1067.

725.Roser M., Fischer D., Kissel T. (1998) Surface-modified biodegradable albumin nanoand microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur.J.Pharm.Biopharm., 46, 255-263.

726.Woodle M.C., Lasic D.D. (1992) Sterically stabilized liposomes. Biochim.Biophys.Acta, 1113, 171-199.

727.Torchilin V.P. (2002) PEG-based micelles as carriers of contrast agents for different imaging modalities. Adv.Drug Deliv.Rev., 54, 235-252.

728.Lee C.M., Choi Y., Huh E.J., Lee K.Y., Song H.C., Sun M.J., Jeong H.J., Cho C.S., Bom H.S. (2005) Polyethylene glycol (PEG) modified 99mTc-HMPAO-liposome for improving blood circulation and biodistribution: the effect of the extent of PEGylation.

Cancer Biother.Radiopharm., 20, 620-628.

729.Wang J., Del Rosario L.S., Demirdirek B., Bae A., Uhrich K.E. (2008) Comparison of PEG chain length and density on amphiphilic macromolecular nanocarriers: Self-assembled and unimolecular micelles. Acta Biomater., 5, 883-892.

730.Gref R., Luck M., Quellec P., Marchand M., Dellacherie E., Harnisch S., Blunk T., Muller R.H. (2000) "Stealth" corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf.B Biointerfaces., 18, 301-313.

731.Awasthi V.D., Garcia D., Goins B.A., Phillips W.T. (2003) Circulation and biodistribution profiles of long-circulating PEG-liposomes of various sizes in rabbits. Int.J.Pharm., 253, 121-132.

732.Prencipe G., Tabakman S.M., Welsher K., Liu Z., Goodwin A.P., Zhang L., Henry J., Dai H. (2009) PEG branched polymer for functionalization of nanomaterials with ultralong blood circulation. J.Am.Chem.Soc., 131, 4783-4787.

733.Shi B., Fang C., Pei Y. (2006) Stealth PEG-PHDCA niosomes: effects of chain length of PEG and particle size on niosomes surface properties, in vitro drug release, phagocytic uptake, in vivo pharmacokinetics and antitumor activity. J.Pharm.Sci., 95, 1873-1887.

734.Kanter P.M., Bullard G.A., Ginsberg R.A., Pilkiewicz F.G., Mayer L.D., Cullis P.R., Pavelic Z.P. (1993) Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D- 99) versus free doxorubicin in beagle dogs. In Vivo, 7, 17-26.

243

735.Bogner J.R., Kronawitter U., Rolinski B., Truebenbach K., Goebel F.D. (1994) Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma.

J.Acquir.Immune.Defic.Syndr., 7, 463-468.

736.Uziely B., Jeffers S., Isacson R., Kutsch K., Wei-Tsao D., Yehoshua Z., Libson E., Muggia F.M., Gabizon A. (1995) Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J.Clin.Oncol., 13, 1777-1785.

737.Allen T.M., Cheng W.W., Hare J.I., Laginha K.M. (2006) Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer. Anticancer Agents Med.Chem., 6, 513-

738.Allen T.M., Mumbengegwi D.R., Charrois G.J. (2005) Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Clin.Cancer Res., 11, 3567-3573.

739.Minisini A.M., Andreetta C., Fasola G., Puglisi F. (2008) Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer. Expert.Rev.Anticancer Ther., 8, 331-342.

740.O'Brien M.E. (2008) Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer. Anticancer Drugs, 19, 1-7.

741.Udhrain A., Skubitz K.M., Northfelt D.W. (2007) Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma. Int.J.Nanomedicine., 2, 345-352.

742.Perez-Lopez M.E., Curiel T., Gomez J.G., Jorge M. (2007) Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer. Anticancer Drugs, 18, 611-617.

743.Moghimi S.M. (2003) Modulation of lymphatic distribution of subcutaneously injected poloxamer 407-coated nanospheres: the effect of the ethylene oxide chain configuration. FEBS Lett., 540, 241-244.

744.Jeon S.I., Lee J.H., Andrade J.D., De Gennes P.J. (1991) Protein-surface interactions in the presence of polyethylene oxide. J.Coll.Interface Sci., 142, 149-158.

745.Chen H., Hu X., Zhang Y., Li D., Wu Z., Zhang T. (2008) Effect of chain density and conformation on protein adsorption at PEG-grafted polyurethane surfaces. Colloids Surf.B Biointerfaces., 61, 237-243.

746.Gessner A., Paulke B.R., Muller R.H., Goppert T.M. (2006) Protein rejecting properties of PEG-grafted nanoparticles: influence of PEG-chain length and surface density evaluated by two-dimensional electrophoresis and bicinchoninic acid (BCA)-proteinassay. Pharmazie, 61, 293-297.

747.Ishida T., Harada M., Wang X.Y., Ichihara M., Irimura K., Kiwada H. (2005) Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes.

J.Control Release, 105, 305-317.

748.Dunn S.E., Brindley A., Davis S.S., Davies M.C., Illum L. (1994) Polystyrene-poly (ethylene glycol) (PS-PEG2000) particles as model systems for site specific drug delivery. 2. The effect of PEG surface density on the in vitro cell interaction and in vivo biodistribution. Pharm.Res., 11, 1016-1022.

749.Neu M., Germershaus O., Behe M., Kissel T. (2007) Bioreversibly crosslinked polyplexes of PEI and high molecular weight PEG show extended circulation times in vivo.

J.Control Release, 124, 69-80.

750.Ambegia E., Ansell S., Cullis P., Heyes J., Palmer L., MacLachlan I. (2005) Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. Biochim.Biophys.Acta, 1669, 155-163.

751.Xu H., Deng Y., Chen D., Hong W., Lu Y., Dong X. (2008) Esterase-catalyzed dePEGylation of pH-sensitive vesicles modified with cleavable PEG-lipid derivatives.

J.Control Release, 130, 238-245.

752.Garinot M., Mignet N., Largeau C., Seguin J., Scherman D., Bessodes M. (2007) Amphiphilic polyether branched molecules to increase the circulation time of cationic particles. Bioorg.Med.Chem., 15, 3176-3186.

753.Han H.D., Lee A., Hwang T., Song C.K., Seong H., Hyun J., Shin B.C. (2007) Enhanced circulation time and antitumor activity of doxorubicin by comblike polymerincorporated liposomes. J.Control Release, 120, 161-168.

244

754.Romberg B., Oussoren C., Snel C.J., Carstens M.G., Hennink W.E., Storm G. (2007) Pharmacokinetics of poly(hydroxyethyl-l-asparagine)-coated liposomes is superior over that of PEG-coated liposomes at low lipid dose and upon repeated administration. Biochim.Biophys.Acta, 1768, 737-743.

755.Gaucher G., Asahina K., Wang J., Leroux J.C. (2009) Effect of poly(N-vinyl- pyrrolidone)-block-poly(D,L-lactide) as coating agent on the opsonization, phagocytosis, and pharmacokinetics of biodegradable nanoparticles. Biomacromolecules., 10, 408-416.

756.Klibanov A.L., Maruyama K., Beckerleg A.M., Torchilin V.P., Huang L. (1991) Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. Biochim.Biophys.Acta, 1062, 142-148.

757.Litzinger D.C., Buiting A.M., van Rooijen N., Huang L. (1994) Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)- containing liposomes. Biochim.Biophys.Acta, 1190, 99-107.

758.Allen T.M., Hansen C., Martin F., Redemann C., Yau-Young A. (1991) Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim.Biophys.Acta, 1066, 29-36.

759.Maruyama K., Yuda T., Okamoto A., Kojima S., Suginaka A., Iwatsuru M. (1992) Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol). Biochim.Biophys.Acta, 1128, 44-49.

760.Litzinger D.C., Huang L. (1992) Amphipathic poly(ethylene glycol) 5000-stabilized dioleoylphosphatidylethanolamine liposomes accumulate in spleen. Biochim.Biophys.Acta, 1127, 249-254.

761.Charrois G.J., Allen T.M. (2003) Rate of biodistribution of STEALTH liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity. Biochim.Biophys.Acta, 1609, 102-108.

762.Nagayasu A., Uchiyama K., Kiwada H. (1999) The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Adv.Drug Deliv.Rev., 40, 75-87.

763.Ishida O., Maruyama K., Sasaki K., Iwatsuru M. (1999) Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice.

Int.J.Pharm., 190, 49-56.

764.Lukyanov A.N., Hartner W.C., Torchilin V.P. (2004) Increased accumulation of PEGPE micelles in the area of experimental myocardial infarction in rabbits. J.Control Release, 94, 187-193.

765.Li S.D., Huang L. (2008) Pharmacokinetics and biodistribution of nanoparticles. Mol.Pharm., 5, 496-504.

766.Brannon-Peppas L., Blanchette J.O. (2004) Nanoparticle and targeted systems for cancer therapy. Adv.Drug Deliv.Rev., 56, 1649-1659.

767.Boerman O.C., Oyen W.J., van Bloois L., Koenders E.B., van der Meer J.W., Corstens F.H., Storm G. (1997) Optimization of technetium-99m-labeled PEG liposomes to image focal infection: effects of particle size and circulation time. J.Nucl.Med., 38, 489-493.

768.Verma D.D., Hartner W.C., Levchenko T.S., Bernstein E.A., Torchilin V.P. (2005) ATP-loaded liposomes effectively protect the myocardium in rabbits with an acute experimental myocardial infarction. Pharm.Res., 22, 2115-2120.

769.Verma D.D., Levchenko T.S., Bernstein E.A., Torchilin V.P. (2005) ATP-loaded liposomes effectively protect mechanical functions of the myocardium from global ischemia in an isolated rat heart model. J.Control Release, 108, 460-471.

770.Verma D.D., Levchenko T.S., Bernstein E.A., Mongayt D., Torchilin V.P. (2006) ATP-loaded immunoliposomes specific for cardiac myosin provide improved protection of the mechanical functions of myocardium from global ischemia in an isolated rat heart model.

J.Drug Target, 14, 273-280.

771.Verma D.D., Hartner W.C., Thakkar V., Levchenko T.S., Torchilin V.P. (2007) Protective effect of coenzyme Q10-loaded liposomes on the myocardium in rabbits with an acute experimental myocardial infarction. Pharm.Res., 24, 2131-2137.

245

772.Ko Y.T., Hartner W.C., Kale A., Torchilin V.P. (2009) Gene delivery into ischemic myocardium by double-targeted lipoplexes with anti-myosin antibody and TAT peptide. Gene Ther., 16, 52-59.

773.Mayer L.D., Nayar R., Thies R.L., Boman N.L., Cullis P.R., Bally M.B. (1993) Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia. Cancer Chemother.Pharmacol., 33, 17-24.

774.Zou Y., Ling Y.H., Reddy S., Priebe W., Perez-Soler R. (1995) Effect of vesicle size and lipid composition on the in vivo tumor selectivity and toxicity of the non-cross-resistant anthracycline annamycin incorporated in liposomes. Int.J.Cancer, 61, 666-671.

775.Kedem O., Katchalsky A. (1958) Thermodynamic analyses of the permeability of biological membranes to non-electrolytes. Biochim.Biophys.Acta, 27, 229-246.

776.Schiffelers R.M., Bakker-Woudenberg I.A., Storm G. (2000) Localization of sterically stabilized liposomes in experimental rat Klebsiella pneumoniae pneumonia: dependence on circulation kinetics and presence of poly(ethylene)glycol coating. Biochim.Biophys.Acta, 1468, 253-261.

777.Drummond D.C., Noble C.O., Hayes M.E., Park J.W., Kirpotin D.B. (2008) Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J.Pharm.Sci., 97, 4696-4740.

778.Matsumura Y. (2008) Polymeric micellar delivery systems in oncology.

Jpn.J.Clin.Oncol., 38, 793-802.

779.Armstrong J.S. (2007) Mitochondrial medicine: pharmacological targeting of mitochondria in disease. Br.J.Pharmacol., 151, 1154-1165.

780.Yamada Y., Akita H., Kogure K., Kamiya H., Harashima H. (2007) Mitochondrial drug delivery and mitochondrial disease therapy – a n approach to liposome-based delivery targeted to mitochondria. Mitochondrion., 7, 63-71.

781.Walkley S.U. (2007) Pathogenic mechanisms in lysosomal disease: a reappraisal of the role of the lysosome. Acta Paediatr.Suppl, 96, 26-32.

782.Callahan J.W., Bagshaw R.D., Mahuran D.J. (2009) The integral membrane of lysosomes: its proteins and their roles in disease. J.Proteomics., 72, 23-33.

783.Hu Z., Zeng L., Huang Z., Zhang J., Li T. (2007) The study of Golgi apparatus in Alzheimer's disease. Neurochem.Res., 32, 1265-1277.

784.Pouton C.W., Wagstaff K.M., Roth D.M., Moseley G.W., Jans D.A. (2007) Targeted delivery to the nucleus. Adv.Drug Deliv.Rev., 59, 698-717.

785.Тараховский Ю.С. (2009) Трансфекция клеток ДНК-липидными комплексами – липоплеками. Биохимия, 74, 1589-1602.

786.Марголис ЛБ, Бергельсон ЛД: (1986) "Липосомы и их взаимодействие с клетками" Москва: Наука.

787.Hu Y., Xie J., Tong Y.W., Wang C.H. (2007) Effect of PEG conformation and particle size on the cellular uptake efficiency of nanoparticles with the HepG2 cells. J.Control Release, 118, 7-17.

788.Foged C., Brodin B., Frokjaer S., Sundblad A. (2005) Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int.J.Pharm., 298, 315-

789.Win K.Y., Feng S.S. (2005) Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials, 26, 2713-2722.

790.Gaumet M., Gurny R., Delie F. (2009) Localization and quantification of biodegradable particles in an intestinal cell model: the influence of particle size. Eur.J.Pharm.Sci., 36, 465-473.

791.Almofti M.R., Harashima H., Shinohara Y., Almofti A., Li W., Kiwada H. (2003) Lipoplex size determines lipofection efficiency with or without serum. Mol.Membr.Biol., 20, 35-43.

792.Doherty G.J., McMahon H.T. (2009) Mechanisms of endocytosis. Annu.Rev.Biochem., 78, 857-902.

793.Liu S.H., Mallet W.G., Brodsky F.M., (2001) Clatrin-mediated endocytosis. "Endocytosis" Marsh M. New York: Oxford Iniversity Press; 1-25.

246

794.Smythe E., Ayscough K.R. (2006) Actin regulation in endocytosis. J.Cell Sci., 119, 4589-4598.

795.Engqvist-Goldstein A.E., Drubin D.G. (2003) Actin assembly and endocytosis: from yeast to mammals. Annu.Rev.Cell Dev.Biol., 19, 287-332.

796.Soldati T. (2003) Unconventional myosins, actin dynamics and endocytosis: a menage a trois? Traffic., 4, 358-366.

797.Hehnly H., Stamnes M. (2007) Regulating cytoskeleton-based vesicle motility. FEBS Lett., 581, 2112-2118.

798.Soldati T., Schliwa M. (2006) Powering membrane traffic in endocytosis and recycling. Nat.Rev.Mol.Cell Biol., 7, 897-908.

799.Weisz O.A. (2003) Organelle acidification and disease. Traffic., 4, 57-64.

800.Caron E., Hall A., (2001) Phagocytosis. "Endocytosis" Marsh M. New York: Oxford University Press; 58-77.

801.Araki N. (2006) Role of microtubules and myosins in Fc gamma receptor-mediated phagocytosis. Front Biosci., 11, 1479-1490.

802.Li C., Macdonald J.I., Hryciw T., Meakin S.O. (2009) Nerve growth factor activation of the TrkA receptor induces cell death, by macropinocytosis, in medulloblastoma Daoy cells. J.Neurochem., 112, 882-899.

803.Amyere M., Mettlen M., Van Der S.P., Platek A., Payrastre B., Veithen A., Courtoy P.J. (2002) Origin, originality, functions, subversions and molecular signalling of macropinocytosis. Int.J.Med.Microbiol., 291, 487-494.

804.Fiorentini C., Falzano L., Fabbri A., Stringaro A., Logozzi M., Travaglione S., Contamin S., Arancia G., Malorni W., Fais S. (2001) Activation of rho GTPases by cytotoxic necrotizing factor 1 induces macropinocytosis and scavenging activity in epithelial cells. Mol.Biol.Cell, 12, 2061-2073.

805.Lee E., Knecht D.A. (2002) Visualization of actin dynamics during macropinocytosis and exocytosis. Traffic., 3, 186-192.

806.Liu N.Q., Lossinsky A.S., Popik W., Li X., Gujuluva C., Kriederman B., Roberts J., Pushkarsky T., Bukrinsky M., Witte M., Weinand M., Fiala M. (2002) Human immunodeficiency virus type 1 enters brain microvascular endothelia by macropinocytosis dependent on lipid rafts and the mitogen-activated protein kinase signaling pathway. J.Virol., 76, 66896700.

807.Seastone D.J., Harris E., Temesvari L.A., Bear J.E., Saxe C.L., Cardelli J. (2001) The WASp-like protein scar regulates macropinocytosis, phagocytosis and endosomal membrane flow in Dictyostelium. J.Cell Sci., 114, 2673-2683.

808.Kerr M.C., Teasdale R.D. (2009) Defining macropinocytosis. Traffic., 10, 364-371.

809.Bruewer M., Utech M., Ivanov A.I., Hopkins A.M., Parkos C.A., Nusrat A. (2005) Interferon-gamma induces internalization of epithelial tight junction proteins via a macropi- nocytosis-like process. FASEB J., 19, 923-933.

810.Greenwood K.P., Daly N.L., Brown D.L., Stow J.L., Craik D.J. (2007) The cyclic cystine knot miniprotein MCoTI-II is internalized into cells by macropinocytosis.

Int.J.Biochem.Cell Biol., 39, 2252-2264.

811.Stan R.V. (2005) Structure of caveolae. Biochim.Biophys.Acta, 1746, 334-348.

812.Pike L.J. (2005) Growth factor receptors, lipid rafts and caveolae: an evolving story.

Biochim.Biophys.Acta, 1746, 260-273.

813.Holowka D., Gosse J.A., Hammond A.T., Han X., Sengupta P., Smith N.L., Wagenknecht-Wiesner A., Wu M., Young R.M., Baird B. (2005) Lipid segregation and IgE receptor signaling: a decade of progress. Biochim.Biophys.Acta, 1746, 252-259.

814.Hancock J.F. (2006) Lipid rafts: contentious only from simplistic standpoints.

Nat.Rev.Mol.Cell Biol., 7, 456-462.

815.Sot J., Collado M.I., Arrondo J.L.R., Alonso A., Goni F. (2002) Triton X-100-resistant bilayers: effect of lipid composition and relevance to the taft phenomenon. Langmuir, 18, 2828-2835.

816.Zajchowski L.D., Robbins S.M. (2002) Lipid rafts and little caves. Compartmentalized signalling in membrane microdomains. Eur.J.Biochem., 269, 737-752.

817.Pelkmans L., Zerial M. (2005) Kinase-regulated quantal assemblies and kiss-and-run recycling of caveolae. Nature, 436, 128-133.

247

818.Sowa G., Pypaert M., Fulton D., Sessa W.C. (2003) The phosphorylation of caveolin-2 on serines 23 and 36 modulates caveolin-1-dependent caveolae formation.

Proc.Natl.Acad.Sci.U.S.A, 100, 6511-6516.

819.Pol A., Martin S., Fernandez M.A., Ingelmo-Torres M., Ferguson C., Enrich C., Parton R.G. (2005) Cholesterol and fatty acids regulate dynamic caveolin trafficking through the Golgi complex and between the cell surface and lipid bodies. Mol.Biol.Cell, 16, 2091-2105.

820.Cheng Z.J., Singh R.D., Sharma D.K., Holicky E.L., Hanada K., Marks D.L., Pagano R.E. (2006) Distinct mechanisms of clathrin-independent endocytosis have unique sphingolipid requirements. Mol.Biol.Cell, 17, 3197-3210.

821.Parton R.G., Simons K. (2007) The multiple faces of caveolae. Nat.Rev.Mol.Cell Biol., 8, 185-194.

822.Tagawa A., Mezzacasa A., Hayer A., Longatti A., Pelkmans L., Helenius A. (2005) Assembly and trafficking of caveolar domains in the cell: caveolae as stable, cargo-triggered, vesicular transporters. J.Cell Biol., 170, 769-779.

823.Machleidt T., Li W.P., Liu P., Anderson R.G. (2000) Multiple domains in caveolin-1 control its intracellular traffic. J.Cell Biol., 148, 17-28.

824.Pelkmans L., Helenius A. (2002) Endocytosis via caveolae. Traffic., 3, 311-320.

825.Le Lay S., Kurzchalia T.V. (2005) Getting rid of caveolins: phenotypes of caveolindeficient animals. Biochim.Biophys.Acta, 1746, 322-333.

826.Anderson R.G., Kamen B.A., Rothberg K.G., Lacey S.W. (1992) Potocytosis: sequestration and transport of small molecules by caveolae. Science, 255, 410-411.

827.Schnitzer J.E., Oh P., Pinney E., Allard J. (1994) Filipin-sensitive caveolae-mediated transport in endothelium: reduced transcytosis, scavenger endocytosis, and capillary permeability of select macromolecules. J.Cell Biol., 127, 1217-1232.

828.Parton R.G., Joggerst B., Simons K. (1994) Regulated internalization of caveolae. J.Cell Biol., 127, 1199-1215.

829.Pelkmans L. (2005) Secrets of caveolaeand lipid raft-mediated endocytosis revealed by mammalian viruses. Biochim.Biophys.Acta, 1746, 295-304.

830.Pani B., Singh B.B. (2009) Lipid rafts/caveolae as microdomains of calcium signaling. Cell Calcium, 45, 625-633.

831.Insel P.A., Patel H.H. (2009) Membrane rafts and caveolae in cardiovascular signaling.

Curr.Opin.Nephrol.Hypertens., 18, 50-56.

832.Patel H.H., Insel P.A. (2009) Lipid rafts and caveolae and their role in compartmentation of redox signaling. Antioxid.Redox.Signal., 11, 1357-1372.

833.Patel H.H., Murray F., Insel P.A. (2008) Caveolae as organizers of pharmacologically relevant signal transduction molecules. Annu.Rev.Pharmacol.Toxicol., 48, 359-391.

834.Patel H.H., Murray F., Insel P.A. (2008) G-protein-coupled receptor-signaling components in membrane raft and caveolae microdomains. Handb.Exp.Pharmacol. 167-184.

835.Thomas C.M., Smart E.J. (2008) Caveolae structure and function. J.Cell Mol.Med., 12, 796-809.

836.Kiss A.L., Botos E. (2009) Endocytosis via caveolae: alternative pathway with distinct cellular compartments to avoid lysosomal degradation? J.Cell Mol.Med., 13, 1228-1237.

837.Sharma P., Sabharanjak S., Mayor S. (2002) Endocytosis of lipid rafts: an identity crisis. Semin.Cell Dev.Biol., 13, 205-214.

838.Sands M.S., Davidson B.L. (2006) Gene therapy for lysosomal storage diseases. Mol.Ther., 13, 839-849.

839.Doyle P.S., Sajid M., O'Brien T., Dubois K., Engel J.C., Mackey Z.B., Reed S. (2008) Drugs targeting parasite lysosomes. Curr.Pharm.Des, 14, 889-900.

840.Panyam J., Labhasetwar V. (2004) Targeting intracellular targets. Curr.Drug Deliv., 1, 235-247.

841.Panyam J., Sahoo S.K., Prabha S., Bargar T., Labhasetwar V. (2003) Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(D,L-lactide-co-glycolide) nanoparticles. Int.J.Pharm., 262, 1-11.

842.Yousif L.F., Stewart K.M., Kelley S.O. (2009) Targeting mitochondria with organellespecific compounds: strategies and applications. Chembiochem., 10, 1939-1950.

843.Hoye A.T., Davoren J.E., Wipf P., Fink M.P., Kagan V.E. (2008) Targeting mitochondria. Acc.Chem.Res., 41, 87-97.

248

844.Holt I.J., Harding A.E., Morgan-Hughes J.A. (1988) Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature, 331, 717-719.

845.Kagan V.E., Wipf P., Stoyanovsky D., Greenberger J.S., Borisenko G., Belikova N.A., Yanamala N., Samhan Arias A.K., Tungekar M.A., Jiang J., Tyurina Y.Y., Ji J., KleinSeetharaman J., Pitt B.R., Shvedova A.A., Bayir H. (2009) Mitochondrial targeting of electron scavenging antioxidants: Regulation of selective oxidation vs random chain reactions. Adv.Drug Deliv.Rev., 61, 1375-1385.

846.Skulachev V.P., Anisimov V.N., Antonenko Y.N., Bakeeva L.E., Chernyak B.V., Erichev V.P., Filenko O.F., Kalinina N.I., Kapelko V.I., Kolosova N.G., Kopnin B.P., Korshunova G.A., Lichinitser M.R., Obukhova L.A., Pasyukova E.G., Pisarenko O.I., Roginsky V.A., Ruuge E.K., Senin I.I., Severina I.I., Skulachev M.V., Spivak I.M., Tashlitsky V.N., Tkachuk V.A., Vyssokikh M.Y., Yaguzhinsky L.S., Zorov D.B. (2009) An attempt to prevent senescence: a mitochondrial approach. Biochim.Biophys.Acta, 1787, 437-461.

847.Liu J., Shen W., Zhao B., Wang Y., Wertz K., Weber P., Zhang P. (2009) Targeting mitochondrial biogenesis for preventing and treating insulin resistance in diabetes and obesity: Hope from natural mitochondrial nutrients. Adv.Drug Deliv.Rev., 61, 1343-1352.

848.Ussher J.R., Lopaschuk G.D. (2009) Targeting malonyl CoA inhibition of mitochondrial fatty acid uptake as an approach to treat cardiac ischemia/reperfusion. Basic Res.Cardiol., 104, 203-210.

849.Pathania D., Millard M., Neamati N. (2009) Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. Adv.Drug Deliv.Rev., 61, 1250-1275.

850.Hagland H., Nikolaisen J., Hodneland L.I., Gjertsen B.T., Bruserud O., Tronstad K.J. (2007) Targeting mitochondria in the treatment of human cancer: a coordinated attack against cancer cell energy metabolism and signalling. Expert.Opin.Ther.Targets., 11, 1055-1069.

851.Murphy M.P. (2008) Targeting lipophilic cations to mitochondria. Biochim.Biophys.Acta, 1777, 1028-1031.

852.Ott M., Norberg E., Zhivotovsky B., Orrenius S. (2009) Mitochondrial targeting of tBid/Bax: a role for the TOM complex? Cell Death.Differ., 16, 1075-1082.

853.Fulda S., Kroemer G. (2009) Targeting mitochondrial apoptosis by betulinic acid in human cancers. Drug Discov.Today, 14, 885-890.

854.Zhao Y., Neuzil J., Wu K. (2009) Vitamin E analogues as mitochondria-targeting compounds: from the bench to the bedside? Mol.Nutr.Food Res., 53, 129-139.

855.Gillet J.P., Macadangdang B., Fathke R.L., Gottesman M.M., Kimchi-Sarfaty C. (2009) The development of gene therapy: from monogenic recessive disorders to complex diseases such as cancer. Methods Mol.Biol., 542, 5-54.

856.Richardson R.M., Varenika V., Forsayeth J.R., Bankiewicz K.S. (2009) Future applications: gene therapy. Neurosurg.Clin.N.Am., 20, 205-210.

857.Wagstaff K.M., Jans D.A. (2009) Nuclear drug delivery to target tumour cells.

Eur.J.Pharmacol., 625, 174-180.

858.Lothstein L., Israel M., Sweatman T.W. (2001) Anthracycline drug targeting: cytoplasmic versus nuclear – a fork in the road . Drug Resist.Updat., 4, 169-177.

859.Taatjes D.J., Koch T.H. (2001) Nuclear targeting and retention of anthracycline antitumor drugs in sensitive and resistant tumor cells. Curr.Med.Chem., 8, 15-29.

860.Zhao X., Li H., Lee R.J. (2008) Targeted drug delivery via folate receptors.

Expert.Opin.Drug Deliv., 5, 309-319.

861.Elnakat H., Ratnam M. (2004) Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv.Drug Deliv.Rev., 56, 1067-1084.

862.Shen F., Wu M., Ross J.F., Miller D., Ratnam M. (1995) Folate receptor type gamma is primarily a secretory protein due to lack of an efficient signal for glycosylphosphatidylinositol modification: protein characterization and cell type specificity. Biochemistry, 34, 5660-5665.

863.Wang H., Ross J.F., Ratnam M. (1998) Structure and regulation of a polymorphic gene encoding folate receptor type gamma/gamma'. Nucleic Acids Res., 26, 2132-2142.

864.Spiegelstein O., Eudy J.D., Finnell R.H. (2000) Identification of two putative novel folate receptor genes in humans and mouse. Gene, 258, 117-125.